Source: Andrew Wynn
Wells Fargo Upgrades Moderna (NASDAQ: MRNA) Amid Positive Flu Vaccine Data
Moderna’s Stock Upgrade
Recently, Moderna (NASDAQ: MRNA), a leading biotechnology company, received an “Outperform” rating upgrade from Wells Fargo. This upgrade is a positive signal indicating potential for future stock growth. The rating is an optimistic outlook on the company’s financial performance, projecting that it will exceed the average market return. This is a significant development for Moderna, as it points towards a promising future and potential return for investors.
This upgrade follows the unveiling of strong Phase 3 clinical trial results for Moderna’s seasonal flu vaccine, mRNA-1010. The company reported that the vaccine demonstrated superior efficacy compared to standard flu vaccines, especially among older adults. This positive data brings Moderna one step closer to achieving regulatory approval for this promising vaccine candidate, with an FDA PDUFA goal date set for August 5.
Moderna’s Innovative Technology
Moderna (NASDAQ: MRNA) is renowned for its innovative messenger RNA (mRNA) technology platform. This groundbreaking technology was instrumental in the development and production of its widely used COVID-19 vaccine. The company’s success in this realm has not only established it as a significant player in the biotechnology industry but also set the stage for future advancements in mRNA-based vaccines and therapeutics.
Their focus now is on expanding this technology to combat a range of infectious diseases. This puts them in direct competition with major pharmaceutical companies such as Pfizer. However, their distinct mRNA technology gives them a unique edge in this competitive market.
Wells Fargo’s Confidence in Moderna
On May 8, 2026, Wells Fargo upgraded Moderna to Outperform from Equal Weight. An Outperform rating indicates that the firm expects the stock to perform better than the broader market. At the time of the upgrade, Moderna shares were trading at $54.35. This implies a strong confidence in the company’s future prospects and growth potential.
Positive Developments in Moderna’s Vaccine Pipeline
The upgrade by Wells Fargo follows a series of positive developments in Moderna’s vaccine pipeline. As highlighted by financial news outlet Benzinga, the company announced successful Phase 3 clinical trial results for its seasonal flu vaccine candidate, mRNA-1010. The findings were peer-reviewed and published in The New England Journal of Medicine, adding scientific credibility to the results, and strengthening investor confidence in Moderna’s vaccine development capabilities.
The study showed that mRNA-1010 was more effective than a standard-dose flu vaccine in adults aged 50 and older. The vaccine demonstrated an overall relative efficacy of 26.6%. Among participants aged 65 and older, relative efficacy increased to 27.4%. These results highlight the potential of mRNA-1010 as a more efficient alternative to existing flu vaccines, particularly for older adults who are more vulnerable to severe flu complications.
Moderna’s Regulatory Milestone
Following these positive trial results, Moderna is now approaching an important regulatory milestone. With an FDA PDUFA goal date of August 5 for mRNA-1010, the company is gearing up for potential approval and commercialization of this significant vaccine candidate. Regulatory filings for mRNA-1010 are also under review in Europe, Canada, and Australia, with potential approvals beginning in 2026.
As of now, the stock is trading at $51.11, giving Moderna a market capitalization of approximately $20.28 billion. This positive trajectory, combined with promising vaccine developments, suggests an optimistic future for Moderna in the biotechnology market.